As Novartis awaits the FDA decision on its spinal muscular atrophy (SMA) gene-therapy, Zolgensma, the company that developed the treatment for the rare, deadly inherited disorder, AveXis, presented data snapshots from ongoing trials on Sunday, prompting analysts to suggest that the one-shot therapy was looking comparable to Biogen’s approved Spinraza.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,